2Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839 for patients with advanced non-small cell lung cancer (IDEAL- 1 ) [ J ]. Proc Am Soc Clin Oncol, 2002, 21:1188a
3Kris M, Natale R, Herbst R, et al. A phase Ⅱ trial of ZD1839 in advanced NSCLC patients who had failed platinum and docetaxel based regimens (IDEAL-2) [J]. Proc Am Soc Clin Onco, 2002,21: 1166a
4Giaccone G, Johnson D H, Manegold C, et al. A phase Ⅲ clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1 ) [J]. Ann Oncol, 2002, 13(Suppl. 5): 2a
5Johnson D H, Herbst R, Giaccone G, et al. ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC):Results from a phase Ⅲ clinical trial (INTACT 2) [J] . Ann Oncol, 2002, 13 (Suppl. 5): 127a
6Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor [J] . Clin Cancer Res, 2000, 6(5):2053 - 2063
